Clinical implications of pharmacokinetics of sunitinib malate and N-desethyl-sunitinib plasma concentrations for treatment outcome in metastatic renal cell carcinoma patients.

about

Clinical implications of pharmacokinetics of sunitinib malate and N-desethyl-sunitinib plasma concentrations for treatment outcome in metastatic renal cell carcinoma patients.

Item

http://www.wikidata.org/entity/Q55382774

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Clinical implications of pharm ...... renal cell carcinoma patients.

@en

Clinical implications of pharm ...... renal cell carcinoma patients.

@nl

type

Item

label

Clinical implications of pharm ...... renal cell carcinoma patients.

@en

Clinical implications of pharm ...... renal cell carcinoma patients.

@nl

prefLabel

Clinical implications of pharm ...... renal cell carcinoma patients.

@en

Clinical implications of pharm ...... renal cell carcinoma patients.

@nl

P1476

Clinical implications of pharm ...... renal cell carcinoma patients.

@en

P2093

Atsushi Maeno

http://www.w3.org/2001/XMLSchema#string

Hiroshi Tsuruta

http://www.w3.org/2001/XMLSchema#string

Kazuyuki Numakura

http://www.w3.org/2001/XMLSchema#string

Makoto Takahashi

http://www.w3.org/2001/XMLSchema#string

Masatomo Miura

http://www.w3.org/2001/XMLSchema#string

Mingguo Huang

http://www.w3.org/2001/XMLSchema#string

Mitsuru Saito

http://www.w3.org/2001/XMLSchema#string

Nobuhiro Fujiyama

http://www.w3.org/2001/XMLSchema#string

Norihiko Tsuchiya

http://www.w3.org/2001/XMLSchema#string

Ryoma Igarashi

http://www.w3.org/2001/XMLSchema#string

P2860

Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer.

Assessment of Sunitinib-Induced Toxicities and Clinical Outcomes Based on Therapeutic Drug Monitoring of Sunitinib for Patients With Renal Cell Carcinoma.

Population Pharmacokinetic/Pharmacodynamic Modeling of Sunitinib by Dosing Schedule in Patients with Advanced Renal Cell Carcinoma or Gastrointestinal Stromal Tumor

Assessment of ethnic differences in sunitinib outcome between Caucasian and Asian patients with metastatic renal cell carcinoma: a meta-analysis.

Pharmacokinetically guided sunitinib dosing: a feasibility study in patients with advanced solid tumours.

A phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma: insights into the treatment, efficacy and safety.

Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis.

Review of therapeutic drug monitoring of anticancer drugs part two--targeted therapies.

Individualized dosing of tyrosine kinase inhibitors: are we there yet?

Role of sunitinib and SU12662 on dermatological toxicities in metastatic renal cell carcinoma patients: in vitro, in vivo, and outcomes investigation.

P304

25277-25284

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.25423

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-05-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29861870

http://www.w3.org/2001/XMLSchema#string

P932

5982748

http://www.w3.org/2001/XMLSchema#string